Astellas Pharma and Immunomic Therapeutics expand collaboration
US privately-held clinical-stage biotech firm Immunomic Therapeuticsand Japanese pharma major Astellas Pharma (TYO: 4503) have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans.
The LAMP-vax technology enhances the effectiveness of DNA vaccines. It has the ability to make DNA vaccines work, which potentially enables effective vaccinations for a wide spectrum of diseases.
Earlier this year, 2015, Immunomic and Astellas entered into an exclusive license agreement for Japan to develop and commercialize ASP4070 (previously known as JRC2-LAMP-vax) designed to treat allergies induced by Japanese red cedar pollen, worth a potential $70 million to the US firm; Astellas initiated a Phase I trial of ASP4070 in Japan this year (The Pharma Letter February 3). Irrespective of the new agreement, this initial agreement remains in effect.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze